Clinical Trials Browser

Completed × trametinib × Breast × Clear all

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

NCT01155453 2020-12-09

A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients

Phase 1 Completed

113 enrolled

BreastGastrointestinal

Pancreatic Neoplasms, Triple Negative Breast Neoplasms

NCT01467310 2020-09-02

Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212

Phase EARLY_PHASE1 Completed

15 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01964924 2019-09-20

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer

Phase 2 Completed

37 enrolled 17 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01138085 2017-11-13

Safety, Pharmacokinetics (PK) of AKT and MEK Combination

Phase 1 Completed

240 enrolled

BreastGynecologic

Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms